Tag: multiple myeloma

Oncotarget News

Figure 7: ER stress signaling plays an important role in mediating GZ17-6.02/bortezomib lethality

GZ17-6.02 With Proteasome Inhibitors Kills Multiple Myeloma Cells

March 6, 2024

We believe that developing GZ17-6.02 as a novel multiple myeloma agent potentially opens up a multitude of novel opportunities to develop therapeutic approaches which will prolong patient survival.”BUFFALO,... read more

Figure 1: Ruxolitinib exerts its anti-myeloma effects through several mechanisms.

Oncotarget

Evaluation of Ruxolitinib, a Janus Kinase Inhibitor, in Multiple Myeloma

February 7, 2024

the results of the studies presented in this review will hopefully provide the impetus for conducting additional preclinical and clinical studies to evaluate RUX in the setting of MM as... read more

Figure 1: Histological analysis of iliac crest bone biopsy.

Oncotarget

Bone Marrow Adipocytes Provide Early Sign of Progression from MGUS to Multiple Myeloma

January 22, 2024

bone marrow adipocyte density, size, and roundness are significantly different between [MGUS and MM] and could provide early signs for progression [...] to MM.”BUFFALO, NY- January 22, 2024 – A new... read more

Figure 3: Patient examples of inverse correlation of BCMA and FLC changes during course of therapy.

Oncotarget

BCMA+ EV Levels Correlate With Myeloma Response to Belantamab-Mafodotin

December 6, 2023

Measurement of BCMA-EV can thus help in identifying resistance mechanisms and side effects of BCMA targeted therapies in future studies.”BUFFALO, NY- December 6, 2023 – A new research paper was... read more

Oncotarget

Oncotarget | Serine Protease Matriptase Inhibits Migration and Proliferation in Multiple Myeloma Cells

November 7, 2022

We demonstrate that matriptase overexpression in vitro was associated with reduced myeloma cell proliferation and that matriptase significantly inhibited myeloma cell migration.”BUFFALO, NY- November 7, 2022 – A new research... read more